Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations,
Lupin Ltd Q1FY25; 78% rise in Profits
Categories
Branded Drug
Sanofi India Ltd Q1FY25; 16% fall in Profits
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for
Unichem Laboratories Ltd Q4FY24; 7% rise in Revenue
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. Financial Results: Unichem Laboratories Ltd reported Revenues
Suven Pharmaceuticals Ltd Q4FY24; 57% fall in Profits
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process
Sun Pharmaceuticals Industries Ltd Q4FY24; 34% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Sun Pharma Advanced Research Company Ltd Q4FY24; 65% fall in Revenue
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. Financial Results: Sun
Procter & Gamble Health Ltd Q4FY24; 20% fall in Profits
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals
Piramal Pharma Ltd Q4FY24; 102% rise in Profits
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and
Pfizer Ltd Q4FY24; 38% rise in Profits
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also
Torrent Pharmaceuticals Ltd Q3FY24; 52% rise in Profits
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.
Shilpa Medicare Ltd Q3FY24; 9% rise in Revenue
Shilpa Medicare is engaged in the business of high quality Active Pharmaceuticals Ingredients (APIs), Intermediates, Formulations, New Drug delivery system, Peptides, Biotech
Sanofi India Ltd Q3FY24; 5% rise in Profits
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues for Q3FY24
Pfizer Ltd Q3FY24; 14% fall in Profits
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also
Marksans Pharma Ltd Q3FY24; 34% rise in Profits
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q3FY24 of
Divi’s Laboratories Ltd Q3 FY24 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q3 FY24 Earnings Concall Growth and Performance Witnessed a steady 3Q driven by expanding market
Sun Pharmaceuticals Industries Ltd Q3FY24; 17% rise in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
Divi’s Laboratories Ltd Q2 FY24 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY24 Earnings Concall Business Overview Anticipating growth opportunities in contrast media, sartans, soon-to-expire patented
Divi’s Laboratories Ltd Q4 FY23 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:11:30] Tushar Manudhane from Motilal Oswal asked if backward
Torrent pharma Q3FY23 net profit rises by 14 percent
Torrent Pharma reported that its consolidated net profit increased by 14 per cent to INR 283 crore in the third quarter ended
Zydus lifescience net profit soars by 23% in Q3FY23
Zydus Lifesciences Ltd reported a 23 per cent rise in consolidated net profit at INR 631 crore for the third quarter ended
Zydus Lifesciences Q3FY23 net profit rises by 23%; Revenue soars 20%
Zydus Lifesciences Ltd reported a 23 per cent rise in consolidated net profit at INR 631 crore for the third quarter ended